Business
Sierra Reports Preclinical Data for Chk1 Inhibitor
Sierra Reports Preclinical Data for Chk1 Inhibitor.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0638V Sareum Holdings PLC 31 October 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n31 October 2017\n\n\n\n\n \n \nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy\n- SRA737 demonstrates synergy with replication stress-inducing agents -\n- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -\n- SRA737 potentiated by novel sub-therapeutic gemcitabine dosing -\nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate Chk1 inhibitor, SRA737, reported preclinical data supporting the ongoing clinical development strategy. The results were presented in a poster on 29 October at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Philadelphia, PA, USA. \n\"The data generated from these experiments are consistent with recent findings from our research and demonstrate that a potent and selective Chk1 inhibitor such as SRA737 can effectively synergize with sub-therapeutic doses of gemcitabine to induce replication catastrophe and tumor cell death,\" said Dr. Alan R. Eastman, Professor at the Geisel School of Medicine at Dartmouth and the founding Director of the Molecular Therapeutics Research Program of the Norris Cotton Cancer Center at Dartmouth-Hitchcock. \"I look forward to results from the clinical study Sierra is conducting which translates this novel strategy for the treatment of patients with advanced cancers.\" \n\"Chk1 is essential for managing replication stress (RS), which is intrinsically elevated in certain oncogene-transformed tumors, and can also be further enhanced by chemotherapeutic drugs like gemcitabine. While gemcitabine likely causes RS by depleting deoxynucleotide (dNTP) and damaging DNA, Chk1 protects against RS through a variety of molecular mechanisms. Consequently, tumor cells become highly reliant on Chk1 to manage replication stress and its downstream consequences in order to survive and continue to proliferate,\" added Dr. Christian Hassig, Senior Vice President of Research at Sierra Oncology. \"Through our research, we have demonstrated that SRA737 has the potential to syner...